FDA Approves Gene Therapy for Kids 2+ With Sickle Cell

The FDA just opened the door to healthier futures for thousands of young children living with sickle cell disease, approving the first gene therapy for patients as young as 2 years old.

Casgevy, a groundbreaking treatment that uses CRISPR gene-editing technology, had been available since 2023 for patients 12 and older. Now, the youngest and most vulnerable patients can access this potentially life-changing therapy during a critical window for intervention.

Sickle cell disease affects about 100,000 Americans, predominantly in African American and Hispanic communities. The inherited blood disorder transforms healthy round red blood cells into crescent shapes that can block blood vessels, causing severe pain, oxygen deprivation, and organ damage that starts in infancy.

The therapy works like precise molecular scissors. Doctors remove a patient's blood stem cells, edit them using CRISPR to boost production of a protective form of hemoglobin, then return the cells to the body. This one-time treatment can eliminate the need for regular blood transfusions that many patients rely on to stay stable.

"Making this therapy available to younger patients opens a critical window for intervention and gives these children a meaningful chance at a healthier future," said Dr. Megha Kaushal, a pediatric hematologist at the FDA.

The Ripple Effect

The timing of this approval carries extra weight. Just as the FDA expanded access, 23-year-old Daniel Cressy became Louisiana's first patient cured by Casgevy after two years of treatment in New Orleans.

Louisiana has more sickle cell cases than any other state. Cressy, diagnosed as an infant and living with years of complications, can now pursue his dream of becoming a pilot.

For families who've watched their children endure painful episodes and hospital stays from birth, this expanded approval means hope can start earlier. Instead of managing symptoms through childhood, parents can now consider a potential cure before their children even start preschool.

The FDA fast-tracked this approval through expedited review programs designed for diseases with significant unmet medical needs. Before gene therapy, the only cure was a high-risk stem cell transplant that wasn't an option for most families.

Thousands of young children and their families now have access to a treatment that could rewrite their health stories from the very beginning.